Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB093 (glibenclamide for injection) for large hemispheric infarction
CTR20202191Phase 3Terminated
- Sponsor
- Biogen
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of glibenclamide in large hemispheric infarction (LHI), cerebral edema, ischemic stroke, sponsored by Biogen. Started Nov 2020; status: terminated.
02
Drugs
glibenclamide
03
Conditions
large hemispheric infarction (LHI)cerebral edemaischemic stroke
Beyond the preview
Go deeper on CTR20202191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202191.